Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score
about
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.The McGill Brisbane Symptom Score in relation to survival in pancreatic adenocarcinoma: a validation study.A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
P2860
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score
@en
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score.
@nl
type
label
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score
@en
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score.
@nl
prefLabel
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score
@en
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score.
@nl
P2093
P2860
P50
P356
P1476
Pancreatic cancer and predicto ...... McGill Brisbane Symptom Score
@en
P2093
Jad Aboukhalil
Jeffrey S Barkun
Mohammad H Jamal
Peter P Metrakos
Prosanto Chaudhury
P2860
P304
P356
10.1111/HPB.12085
P577
2013-03-22T00:00:00Z